0001415889-22-011356.txt : 20221114
0001415889-22-011356.hdr.sgml : 20221114
20221114170027
ACCESSION NUMBER: 0001415889-22-011356
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221109
FILED AS OF DATE: 20221114
DATE AS OF CHANGE: 20221114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dake Benjamin T
CENTRAL INDEX KEY: 0001869248
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 221387183
MAIL ADDRESS:
STREET 1: C/O AEROVATE THERAPEUTICS, INC.
STREET 2: 200 BERKELEY STREET, FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-11142022_051101.xml
X0306
4
2022-11-09
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001869248
Dake Benjamin T
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
SEE REMARKS
Common Stock
2022-11-09
4
M
0
14000
2.14
A
14000
D
Common Stock
2022-11-09
4
S
0
14000
17.9055
D
0
D
Common Stock
2022-11-10
4
M
0
1800
2.14
A
1800
D
Common Stock
2022-11-10
4
S
0
1800
20.0955
D
0
D
Common Stock
2022-11-11
4
M
0
6198
2.14
A
6198
D
Common Stock
2022-11-11
4
S
0
4452
20.3851
D
1746
D
Common Stock
2022-11-11
4
S
0
1625
21.4127
D
121
D
Common Stock
2022-11-11
4
S
0
121
22.1978
D
0
D
Stock Option (Right to Buy)
2.14
2022-11-09
4
M
0
14000
0
D
2031-04-01
Common Stock
14000
262598
D
Stock Option (Right to Buy)
2.14
2022-11-10
4
M
0
1800
0
D
2031-04-01
Common Stock
1800
260798
D
Stock Option (Right to Buy)
2.14
2022-11-11
4
M
0
6198
0
D
2031-04-01
Common Stock
6198
254600
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.49 to $18.26, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.406, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.965, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.02 to $21.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.16 to $22.205, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.
Officer Title: President, Chief Operating Officer and Secretary
/s/ George A. Eldridge, Attorney-in-Fact
2022-11-14